wound healing in diabetes patients with foot ulcer MedDRA version: 8.1 Level: LLT Classification code 10048037 Term: Wound healing disturbance of
Conditions
Interventions
Trade Name: NeoRecormon Multidose 50.000 I.E.
Lyophilisat und Lösungsmittel zur Herstellung einer Injektionslösung (5.000 I.E./ml)
Pharmaceutical Form: Powder and solvent for solution for injection
IN
Sponsors
EPOPLUS GmbH & Co.KG
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Diabetic patients with foot ulcer below the ankle will be randomised into 2 treatment arms: a. diagnosis of diabetes and neuropathic ulcer Wagner I or II (as indicated by a neuropathy deficit score 6-10, palpable foot pulses and an ABI-index =1.0) or b. diagnosis of diabetes and ulcer Wagner I / II or wounds after amputations in patients with peripheral arterial occlusive disease (as indicated by the presence of one of the following: missing foot pulses and an ABI-index =0.8), or a history of insufficient vascularisation on the target leg*). *Angiographically documented peripheral arterial occlusive disease and no surgical or endovascular treatment option. 2. Ulcer size over 0.5 cm2. 3. Male or female aged = 18 years. 4. Signed written informed consent to participate in this trial. 5. Female of childbearing potential with a negative pregnancy test, and agrees to use an acceptable contraceptive method (hormonal or IUD) throughout the study. 6. HbA1c 10% then stable blood glucose level within the last 4 weeks, i.e. fasting blood glucose value =65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: 1. Pregnant or nursing women. 2. Myeloplastic or proliferative disease. 3. Known infection with hepatitis B or hepatitis C or HIV. 4. Therapy with rHuEPO or analogic medicine within the last 6 months. 5. Bleeding episodes which affect the Hb value or known gastro-intestinale bleedings within the last 3 months. 6. Known or suspected intolerance to erythropoetic factors, e.g. NeoRecormon®, Aranesp®, Erypo®. 7. Treatment with systemic chemotherapy or radiotherapy or immunosuppressives or systemic corticosteroids within the last 6 months prior to treatment start. 8. Previous therapy with growth factors, e.g. GM-CSF, VEGF in the last 6 months. 9. Intake of any medication which interacts with epoetin beta (e.g. Cyclosporin). 10. Uncontrolled systolic blood pressure > 160 mmHg (supine) and/or diastolic blood pressure > 100 mmHg. 11. Pulmonary embolism and deep leg venous thrombosis with a history of venous thromboembolic disease. 12. Stroke, instable angina pectoris, STEMI or NSTEMI within the last 3 month. 13. Psychiatric disease or chronic cerebellar fits. 14. Scheduled for vascular surgery or any other intervention surgery within 4 weeks to trial start or during the trial or patients, who could benefit from vascular surgery or other invasive intervention. 15. Thromboembolism and/or thromboses. 16. Atrial fibrillation or atrial septum defect. 17. Transient ischaemic attack (TIA) within the last 3 month 18. Prolonged reversible ischemic neurological deficit (PRIND) within the last 3 month 19. Artificial heart valves (mechanical or biological) 20. Alcohol or drug of abuse. 21. Non-compliance and/or participation in a clinical trial within the last 3 months prior to screening. 22. Patients in dialysis program or chronical renal failure Grad IV. 23. Patients with known bleedings, MCV below normal ranges, and iron deficiency anemia 24. Hemoglobin, hematocrit and platelet count above the upper limit of normal according to the local laboratory 25. At the time point of randomization wound infections treated with antibiotics.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To evaluate the effects of a systemic treatment with erythropoietin on wound closure in patients with diabetes and diabetic foot syndrome;Secondary Objective: The secondary objectives of the study are: a) To evaluate the wound healing, i.e. area of the target (biggest) ulcer, from baseline to week 13 (percentage and absolute change). b) To evaluate the microcirculation (only at selected study sites). c) To describe the one-year survival status/amputation rate/recurrence of target ulcer. d) To evaluate the wound healing, i.e. depth of the target ulcer from baseline to week 13. e) To evaluate the time to wound closure. f) To evaluate the reduction of pain. g) Safety and tolerability. ;Primary end point(s): Primary endpoint is complete wound closure of the target ulcer. | — |
Countries
Bulgaria, Germany
Outcome results
None listed